A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/16/11/1811/302788/mdi365.pdf
Reference32 articles.
1. An advance in small-cell lung cancer treatment—more or less;Laskin;J Natl Cancer Inst,2003
2. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer;von Pawel;J Clin Oncol,1999
3. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group.
4. Expression of the gastrin-releasing peptide gene in human small-cell lung cancer. Evidence for alternative processing resulting in three distinct mRNAs;Sausville;J Biol Chem,1986
5. Insulin-like growth factor-I can mediate autocrine proliferation of human small-cell lung cancer cell lines in vitro;Nakanishi;J Clin Invest,1988
Cited by 129 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Actionable Driver Events in Small Cell Lung Cancer;International Journal of Molecular Sciences;2023-12-20
2. Integrative Analysis of a Large Real-World Cohort of Small Cell Lung Cancer Identifies Distinct Genetic Subtypes and Insights into Histologic Transformation;Cancer Discovery;2023-04-16
3. Pulmonary cancers across different histotypes share hybrid tuft cell/ionocyte-like molecular features and potentially druggable vulnerabilities;Cell Death & Disease;2022-11-19
4. Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histological transformation;2022-07-29
5. Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell Lung Cancer;International Journal of Molecular Sciences;2022-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3